Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $6.74 USD
Change Today -0.2899 / -4.12%
Volume 704.0K
SGYP On Other Exchanges
Symbol
Exchange
NASDAQ GS
NASDAQ CM
Frankfurt
As of 2:03 PM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

synergy pharmaceuticals inc (SGYP) Snapshot

Open
$7.16
Previous Close
$7.03
Day High
$7.16
Day Low
$6.72
52 Week High
07/7/15 - $10.15
52 Week Low
10/10/14 - $2.45
Market Cap
758.0M
Average Volume 10 Days
2.1M
EPS TTM
$-1.18
Shares Outstanding
112.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SYNERGY PHARMACEUTICALS INC (SGYP)

synergy pharmaceuticals inc (SGYP) Related Businessweek News

No Related Businessweek News Found

synergy pharmaceuticals inc (SGYP) Details

Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development of drugs to treat gastrointestinal (GI) disorders and diseases. Its lead product candidate is plecanatide, a guanylyl cyclase C receptor agonist that is in Phase III clinical trials to treat chronic idiopathic constipation GI disorders; and for the treatment of constipation-predominant irritable bowel syndrome GI disorders. The company is also developing SP-333, which is in Phase II clinical trials to treat opioid induced constipation, as well as in Phase Ib clinical trials to treat ulcerative colitis. Synergy Pharmaceuticals Inc. is headquartered in New York, New York.

35 Employees
Last Reported Date: 03/16/15

synergy pharmaceuticals inc (SGYP) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $750.0K
Principal Financial Officer, Principal Accoun...
Total Annual Compensation: $276.0K
Chief Medical Officer and Executive Director
Total Annual Compensation: $445.3K
Chief Scientific Officer
Total Annual Compensation: $392.0K
Compensation as of Fiscal Year 2014.

synergy pharmaceuticals inc (SGYP) Key Developments

Synergy Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Synergy Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company's net loss was $33.668 million or $0.34 per basic and diluted share against $25.920 million or $0.28 per basic and diluted share a year ago. Loss from operations was $26.919 million against $26.758 million a year ago. For the six months, the company's net loss was $61.057 million or $0.62 per basic and diluted share against $42.145 million or $0.45 per basic and diluted share a year ago. Loss from operations was $49.723 million compared with $43.235 million a year ago. Net cash used in operating activities was $49.0 million as compared to $39.5 million a year ago.

Synergy Pharmaceuticals Announces Positive Results in the Second Phase 3 Trial of Plecanatide in Patients with Chronic Idiopathic Constipation

Synergy Pharmaceuticals Inc. announced positive results from the second of two pivotal phase 3 clinical trials evaluating the efficacy and safety of two different plecanatide treatment doses (3.0 mg and 6.0 mg), taken as a tablet once-a-day, in 1,337 adult patients with chronic idiopathic constipation (CIC). Preliminary analysis of the data indicates that both plecanatide 3.0 mg and 6.0 mg doses met the study's primary endpoint and demonstrated statistical significance in the proportion of patients in the intention-to-treat population who were durable overall responders compared to placebo during the 12-week treatment period (20.1% in 3.0 mg and 20.0% in 6.0 mg dose groups compared to 12.8% in placebo; p=0.004 for both doses). The durable overall responder endpoint is the current FDA endpoint required for US approval in CIC. Importantly, plecanatide was safe and well tolerated at both doses; the most common adverse event was diarrhea, which occurred in 3.2% of patients in 3.0 mg and 4.5% of patients in 6.0 mg dose groups compared to 1.3% of placebo-treated patients. Stool consistency was the key secondary endpoint reported with analyses; both 3.0 mg and 6.0 mg plecanatide doses showed statistically significant improvement from baseline in Bristol Stool Form Scale (BSFS) scores compared to placebo (mean increase of 1.49 in 3.0 mg and 1.50 in 6.0 mg dose groups compared to a mean increase of 0.87 in placebo; p<0.001 for both doses). The observed improvements began at Week 1, continued throughout the 12-week treatment period, and returned towards baseline with no indication of an exaggerated or rebound effect following discontinuation of treatment. 20 patients in the trial (1.4%) experienced serious adverse events but there was no imbalance across treatment groups in either incidences or individual serious adverse events. Overall, the rates of withdrawal from treatment because of an adverse event were low (3.2% in 3.0 mg and 3.8% in 6.0 mg dose groups compared to 3.0% in placebo) and discontinuations due to diarrhea were infrequent (1.1% in 3.0 mg and 1.1% in 6.0 mg dose groups compared to 0.4% in placebo). No clinically relevant abnormalities were observed in serum chemistries, hematology, urinalysis, ECG or vital signs measurements. Synergy plans to present additional data results from both phase 3 CIC trials at appropriate scientific conferences. The company plans to file its first new drug application (NDA) with plecanatide in the CIC indication in January 2016. The plecanatide phase 3 CIC program included two randomized, 12-week, double-blind, placebo-controlled pivotal trials that evaluated the efficacy and safety of two different plecanatide treatment doses (3.0 mg and 6.0 mg), taken as a tablet once-a-day, in patients with CIC. Both trials included a two-week pre-treatment baseline period, a 12-week treatment period, and a two-week post-treatment period. The phase 3 CIC program was designed to support regulatory submission in the U.S. The second phase 3 CIC trial was conducted in the United States and assessed 1,337 adult patients (21.6% males and 78.4% females) that were randomly assigned to take 3.0 mg or 6.0 mg plecanatide or placebo once-a-day during the 12 week treatment period (443 patients in the 3.0 mg dose group, 449 patients in the 6.0 mg dose group and 445 patients in the placebo group). The first phase 3 CIC trial was conducted in North America and assessed 1,346 adult patients (19.2% males and 80.8% females) that were randomly assigned to take 3.0 mg or 6.0 mg plecanatide or placebo once-a-day during the 12 week treatment period (453 patients in the 3 mg dose group, 441 patients in the 6.0 mg dose group and 452 patients in the placebo group). The primary endpoint for both trials was the proportion of durable overall responders (%), which is the current regulatory endpoint required for U.S. approval in CIC. The FDA has defined a durable overall responder as a patient who fulfills both > 3 complete spontaneous bowel movements (CSBMs) per week plus an increase of > 1 CSBM from baseline in the same week, for 9 out of the 12 treatment weeks. In addition, the same patient must be an overall responder for at least 3 of the last 4 treatment weeks in order to be considered a durable overall responder. Plecanatide would be the first drug approved for CIC using the more stringent regulatory requirement for durability in the response. Patients were selected using Rome 3 criteria modified for CIC and had fewer than 3 defecations per week, loose stools occurring rarely without laxatives, inadequate criteria for irritable bowel syndrome with constipation (IBS-C), and at least two of the following applied to at least 25% of defecations: straining during evacuation, lumpy or hard stools, sensation of anorectal obstruction or blockage. Rome 3 requires patients to fulfill the criteria for the last 3 months with symptom onset at least 6 months prior to diagnosis.

Synergy Pharmaceuticals, Inc. Presents at 35th Annual Canaccord Genuity Growth Conference, Aug-13-2015 11:30 AM

Synergy Pharmaceuticals, Inc. Presents at 35th Annual Canaccord Genuity Growth Conference, Aug-13-2015 11:30 AM. Venue: InterContinental Boston, 510 Atlantic Avenue, Boston, MA 02210, United States. Speakers: Gary S. Jacob, Chairman, Chief Executive Officer and President.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SGYP:US $6.74 USD -0.2899

SGYP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergan plc $298.30 USD -1.31
Almirall SA €16.85 EUR +0.12
Ironwood Pharmaceuticals Inc $10.76 USD -0.35
Shire PLC 4,899 GBp +16.00
Sucampo Pharmaceuticals Inc $24.50 USD -2.56
View Industry Companies
 

Industry Analysis

SGYP

Industry Average

Valuation SGYP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SYNERGY PHARMACEUTICALS INC, please visit www.synergypharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.